Project Grant R01CA294696
Award Date
6/5/25
Completion Date
5/31/30
Dollars Obligated
$581K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a 5-year, $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research. The grant will fund research to determine the role of key proteins, including RAD52, HELQ, and POLQ, in backup DNA double-strand break repair pathways in homologous recombination-deficient (HRD) cancers. The research aims to identify additional proteins involved in these alternative repair...
This $238,722 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair pathways in the persistence and acquired drug resistance of cancer cells. The key objectives are to: (1) study persistence mechanisms in BRCA1/2-mutant cancer cells treated with PARP inhibitors, (2) examine how mutagenic DNA repair via...
The National Cancer Institute (NCI) awarded a $523,292 project grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms by which the microhomology-mediated end-joining (MMEJ) DNA repair pathway is suppressed in Ewing sarcoma, an aggressive subtype of bone and soft tissue cancer. The project aims to 1) elucidate how the EWSR1 gene and EWS-FLI1 fusion protein disrupt MMEJ in Ewing sarcoma, 2)...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
The National Cancer Institute (NCI) awarded a $432,614 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Duke University. The grant, awarded on September 1, 2024, will support research to define the relationship between chromosomal instability (CIN), loss of the short arm of chromosome 17 (17P loss), and sensitivity to inhibition of the mitotic regulator NDE1. The research aims to characterize the role of NDE1 in proper chromosome segregation and assess the therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at addressing the rapid development of resistance to targeted therapies for metastatic colorectal cancer. The research will evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and test a novel combination approach of DNA repair inhibition and...
The National Cancer Institute (NCI) awarded a $100,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization located in New York, NY. The grant, running from January 1, 2025 to December 31, 2028, will fund research to develop a nanoparticle-based RNA interference (RNAi) therapy targeting the tumor immune microenvironment in multiple myeloma (MM). The project aims to...
The National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant, with a project period from February 1, 2025 to January 31, 2027, aims to explore the role of aberrant splicing in cancer cell heterogeneity and its potential as targets for novel immunotherapeutic strategies. The research will utilize advanced computational frameworks and multimodal single-cell approaches to...
The National Cancer Institute (NCI) awarded a $3,787,956 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, titled "Investigating and Targeting Replication Stress in Small Cell Lung Cancer," aims to advance the understanding of molecular mechanisms underlying DNA replication stress and identify novel therapeutic strategies to combat acquired chemoresistance in small cell lung cancer (SCLC). The research...